Summary of Significant Accounting Policies (Details Textual) (USD $)
|
3 Months Ended | 12 Months Ended | 0 Months Ended | |
---|---|---|---|---|
Dec. 31, 2014
|
Dec. 31, 2014
|
Dec. 31, 2013
|
Jun. 30, 2014
|
|
Summary Of Significant Accounting Policies [Line Items] | ||||
Ownership percentage attributable to Milestone | 49.90%us-gaap_MinorityInterestOwnershipPercentageByParent | 49.90%us-gaap_MinorityInterestOwnershipPercentageByParent | ||
Warranty expense | $ 79,017us-gaap_ProductWarrantyExpense | $ 97,234us-gaap_ProductWarrantyExpense | ||
Non-Warranty repair income | 60,473mlss_NonWarrantyRepairIncome | 118,344mlss_NonWarrantyRepairIncome | ||
Joint venture owned by the entity | 49.98%us-gaap_EquityMethodInvestmentOwnershipPercentage | 49.98%us-gaap_EquityMethodInvestmentOwnershipPercentage | ||
Common stock, shares issued | 21,404,494us-gaap_CommonStockSharesIssued | 21,404,494us-gaap_CommonStockSharesIssued | 17,759,540us-gaap_CommonStockSharesIssued | |
Gain on Dilutive Effect on Medical Joint Venture stock issuance | 1,363,650us-gaap_DilutiveSecuritiesEffectOnBasicEarningsPerShareOther | |||
Purchase of additional shares | 995,000us-gaap_SubsidiaryOrEquityMethodInvesteeCumulativeNumberOfSharesIssuedForAllTransactions | |||
Purchase of additional shares, value | 447,750us-gaap_SubsidiaryOrEquityMethodInvesteeCumulativeProceedsReceivedOnAllTransactions | |||
Purchase of additional shares, price per share | $ 0.45us-gaap_SaleOfStockPricePerShare | $ 0.45us-gaap_SaleOfStockPricePerShare | ||
Long-lived assets for impairment | 0us-gaap_ImpairmentOfLongLivedAssetsHeldForUse | 0us-gaap_ImpairmentOfLongLivedAssetsHeldForUse | ||
Advertising expenses | 26,569us-gaap_AdvertisingExpense | 30,104us-gaap_AdvertisingExpense | ||
Weighted-average fair value of the individual options granted | $ 2.18us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue | $ 1.62us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue | ||
Options | ||||
Summary Of Significant Accounting Policies [Line Items] | ||||
Outstanding options and warrants | 1,488,796us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount / us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis = mlss_OptionsAndWarrantsMember |
|||
Minimum | ||||
Summary Of Significant Accounting Policies [Line Items] | ||||
Estimated useful lives | 5 years | |||
Maximum | ||||
Summary Of Significant Accounting Policies [Line Items] | ||||
Estimated useful lives | 7 years | |||
Milestone China | ||||
Summary Of Significant Accounting Policies [Line Items] | ||||
Joint venture owned by the entity | 40.00%us-gaap_EquityMethodInvestmentOwnershipPercentage / us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis = country_CN |
|||
Investment in joint venture | 348,651us-gaap_EquityMethodInvestments / us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis = country_CN |
348,651us-gaap_EquityMethodInvestments / us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis = country_CN |
1,000,000us-gaap_EquityMethodInvestments / us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis = country_CN |
|
Distributor price per instrument | $ 1,295mlss_DistributorPricePerInstrument / us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis = country_CN |
|||
Loss on Joint Ventures | $ (810)us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss / us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis = country_CN |
$ (2,025)us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss / us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis = country_CN |
||
Percentage of gain/loss on joint venture | 40.00%mlss_EquityMethodInvestmentSummarizedFinancialInformationPercentageOfNetIncomeLoss / us-gaap_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis = country_CN |
|||
ACS | ||||
Summary Of Significant Accounting Policies [Line Items] | ||||
Ownership percentage attributable to Milestone | 70.00%us-gaap_MinorityInterestOwnershipPercentageByParent / dei_LegalEntityAxis = mlss_AdvancedCosmeticSystemIncMember |
70.00%us-gaap_MinorityInterestOwnershipPercentageByParent / dei_LegalEntityAxis = mlss_AdvancedCosmeticSystemIncMember |
||
Minority interest recorded as noncontrolling interest | 30.00%us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners / dei_LegalEntityAxis = mlss_AdvancedCosmeticSystemIncMember |
30.00%us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners / dei_LegalEntityAxis = mlss_AdvancedCosmeticSystemIncMember |
||
Milestone Medical Inc | ||||
Summary Of Significant Accounting Policies [Line Items] | ||||
Joint venture owned by the entity | 50.00%us-gaap_EquityMethodInvestmentOwnershipPercentage / dei_LegalEntityAxis = mlss_MilestoneMedicalIncMember |
50.00%us-gaap_EquityMethodInvestmentOwnershipPercentage / dei_LegalEntityAxis = mlss_MilestoneMedicalIncMember |
45.50%us-gaap_EquityMethodInvestmentOwnershipPercentage / dei_LegalEntityAxis = mlss_MilestoneMedicalIncMember |
|
Common stock, shares issued | 2,000,000us-gaap_CommonStockSharesIssued / dei_LegalEntityAxis = mlss_MilestoneMedicalIncMember |
X | ||||||||||
- Definition
Distributor price per instrument. No definition available.
|
X | ||||||||||
- Definition
Equity method investment summarized financial information percentage of net income loss. No definition available.
|
X | ||||||||||
- Definition
Non warranty repair income. No definition available.
|
X | ||||||||||
- Details
|
X | ||||||||||
- Definition
Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
X | ||||||||||
- Definition
Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
X | ||||||||||
- Definition
Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
X | ||||||||||
- Definition
Amount of increase (decrease) to net income used for calculating diluted earnings per share (EPS), resulting from the assumed exercise of dilutive convertible securities excluding adjustments related to ESOP convertible preferred stock, stock options, and restrictive stock units. No definition available.
|
X | ||||||||||
- Definition
The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
X | ||||||||||
- Definition
This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
X | ||||||||||
- Definition
The amount of net income (loss) reported by an equity method investment of the entity. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
X | ||||||||||
- Definition
The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale). Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
X | ||||||||||
- Definition
The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity. No definition available.
|
X | ||||||||||
- Definition
The parent entity's interest in net assets of the subsidiary, expressed as a percentage. No definition available.
|
X | ||||||||||
- Definition
The expense charged against earnings for the period pertaining to standard and extended warranties on the entity's goods and services granted to customers. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
X | ||||||||||
- Definition
Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment. No definition available.
|
X | ||||||||||
- Definition
Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction. No definition available.
|
X | ||||||||||
- Definition
The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology. Reference 1: http://www.xbrl.org/2003/role/presentationRef
|
X | ||||||||||
- Definition
Cumulative number of shares issued or sold by the subsidiary or equity method investee on all stock transactions. No definition available.
|
X | ||||||||||
- Definition
Cumulative amount of cash and other consideration received by subsidiary or equity method investee in exchange for shares or stock issued or sold. Include amounts of cash received, fair value of non-cash assets received, fair value of liabilities assumed, and fair value of any other forms of consideration. No definition available.
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|
X | ||||||||||
- Details
|